OTCQX:RHHBY -0.7% ) 115 and 455 Herceptin patents are invalid paving the way for Hospira ( HSP -3.5% ) to market a biosimilar version in Britain. Hospira wants to sell its offering of trastuzumab after Herceptin's core patent expires on
* Roche considering its next steps (Adds Roche and Hospira comment, patent details)
LONDON, April 10 (Reuters) - Hospira has successfully overturned two patents on Roche's top-selling breast cancer drug Herceptin in Britain, clearing the way for it to launch a cheaper copycat version in the country.
intravenously to treat hypertension and assorted heart conditions, is one of those drugs. Last year, two manufacturers -- Hospira ( HSP ) and American Regent, owned by Luitpold Pharmaceuticals -- stopped selling injectable nitroglycerin, making Baxter
establish a meaningful position. Hospira was a longtime holding of the Fund ..... Laboratories, which spun-off Hospira ten years ago. Over ..... Crane Co. 0%, Encana Corp. 0%, Hospira , Inc . 0%, Abbott Laboratories 0
Shares of The Medicines Company ( MDCO -14.7% ) drop after a Delaware court finds that Hospira 's ( HSP +1.6% ) aNDA for a generic bivalirudin does not infringe on Angiomax patents '727 and '343. The court has yet
NEW YORK, March 27 (Reuters) - Hospira Inc has agreed to pay $60 million to resolve a class action lawsuit accusing the drug maker of misleading investors about quality control problems that undermined an initiative to improve the company's margins and operations.
has a lower yield (than Inland). I think it is better run." Lockheed Martin ( LMT ): "Great buyback, great dividend, great management. That is for me." Hospira ( HSP ): "This is a very good company with real Complete Story »
Neupogen in the U.S. in 2014 (including a branded neutropenia product from Teva and biosimilar Epogen competition from Hospira ). However, Teva's setbacks with its long-acting neutropenia products have caused us to increase our U.S. Neulasta
Cubicin is facing a patent challenge from Hospira .If Cubist's CB-315/Surotomycin ..... news was a big win for Cubist, but Hospira has now also challenged the drug's patent. There is a risk that Hospira could prevail in litigation, and Cubicin